RxDoctor Payments Data

Jill Walker, NP

Family · Macon, GANPI 1750818100

Payments from drug & device makers

$3,399in general payments, 2019–2025

Across 80 payments — averaging $42.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • AbbVie$360
  • Astellas Pharma US Inc$154
  • ABC Home Medical Supply, Inc.$150
  • Boston Scientific$113
  • Urovant Sciences Inc$74
  • plus $195 from 6 others

What the payments were for

  • Travel & lodging$97929%
  • Food & beverage$2,32068%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.33$2,352
AbbVie(2 entities)15$360
Astellas Pharma US Inc4$154
ABC Home Medical Supply, Inc.7$150
Boston Scientific8$113
Urovant Sciences Inc4$74
Medtronic2$66
Coloplast2$36
Sumitomo Pharma America, Inc.2$34
Pfizer1$28
GSK1$20
AstraZeneca1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,399 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$34,845
Medicare patients
262
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron333$205,532
MyrbetriqMirabegron301$167,735
Estradiol397$27,283
Trospium Chloride ErTrospium Chloride124$24,122
Methenamine Hippurate91$7,696
PremarinEstrogens, Conjugated16$6,931
Trospium Chloride148$6,163
Darifenacin ErDarifenacin Hydrobromide18$3,120
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$899
Amitriptyline Hcl15$417
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim43$178
Ciprofloxacin Hcl44$158
Fluconazole28$117
Cephalexin11$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$34$205,532333 claims
Astellas Pharma US IncMyrbetriq$154$167,735301 claims
PfizerPremarin$28$6,93116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →